We propose that Nrf2 is central to the phenotypic and morphological changes apparent in FECD and that the pharmacological targeting of Nrf2 would be a valuable avenue for treatment of FECD. This evidence concerns the gene NFE2L2 and Fuchs endothelial corneal dystrophy.